Early Detection Research Network

Spira 80-marker panel plus clinical factors

This biomarker is also known as:
  • 80-gene panel,
  • Spira 80-marker panel plus clinical factors,


This clinicogenomic model incorporates the gene expression pattern of histologcially normal large airway epithelial cells collected at time of bronchoscopy (see 'Spira 80-marker panel for lung cancer') with clinical parameters about lung cancer risk.


There are no datasets associated with this biomarker.

QA State: Curated
HGNC Name:

Panel Details

No member markers defined for this panel.

The following organs have data associated with this biomarker…


Phase: One
QA State: Curated


The Spira 80-marker panel for lung cancer biomarker was developed by using the gene expression patterns obtained from cytologically normal large airway epithelial cells from smokers undergoing bronchoscopy for suspiction of lung cancer. The results from the bronchosopy are 100% specific for lung cancer, but has a limited sensitivity of 30-80% depending ont he stage and location of the cancer. Therefore, difficult decisions must be made regarding care and treatment of patients with potentially early-stage, treatable, curable cancers. By adding the clinical factors to the 80-marker panel, the predictive nature of the model has been improved.

Performance Comment

This clinicogenomic model that contains both clinical factors and gene expression data from the Spira 80-marker panel for lung cancer yields improved sensitivity, specificity, positive value, and negative predictive value over the clinical model alone.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.

No other associated resources found.